220 related articles for article (PubMed ID: 26681756)
1. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.
Gurbel PA; Bliden KP; Turner SE; Tantry US; Gesheff MG; Barr TP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):189-97. PubMed ID: 26681756
[TBL] [Abstract][Full Text] [Related]
2. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.
Kuliopulos A; Gurbel PA; Rade JJ; Kimmelstiel CD; Turner SE; Bliden KP; Fletcher EK; Cox DH; Covic L;
Arterioscler Thromb Vasc Biol; 2020 Dec; 40(12):2990-3003. PubMed ID: 33028101
[TBL] [Abstract][Full Text] [Related]
3. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.
Zhang P; Gruber A; Kasuda S; Kimmelstiel C; O'Callaghan K; Cox DH; Bohm A; Baleja JD; Covic L; Kuliopulos A
Circulation; 2012 Jul; 126(1):83-91. PubMed ID: 22705889
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
5. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
8. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Zhang D; Zhang X; Liu D; Liu T; Cai W; Yan C; Han Y
Cardiovasc Diabetol; 2016 Mar; 15():50. PubMed ID: 27005817
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Rana R; Huang T; Koukos G; Fletcher EK; Turner SE; Shearer A; Gurbel PA; Rade JJ; Kimmelstiel CD; Bliden KP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1368-1380. PubMed ID: 29622563
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
12. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
13. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
[TBL] [Abstract][Full Text] [Related]
14. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
[TBL] [Abstract][Full Text] [Related]
15. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS
Platelets; 2010; 21(3):183-90. PubMed ID: 20201634
[TBL] [Abstract][Full Text] [Related]
18. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
19. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
